The Study of CM326 in Moderate-to-severe Atopic Dermatitis

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of CM326 in moderate-severe atopic dermatitis subjects.

Inclusion Criteria:With confirmed Atopic Dermatitis (AD) at the screening.Age ≥ 18 years and ≤ 75 years, male or female.Have the ability to understand the nature of the study and voluntarily sign the informed consent.Be able to communicate well with investigators and follow up protocol requirements.Exclusion Criteria:Not enough washing-out period for previous therapy.Received allergen specific immunotherapy (desensitization) within 6 months prior to baseline.Major surgery is planned during the study period.Women who are pregnant or breastfeeding, or who plan to become pregnant during the study.